title: Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.
authors.affiliation: Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
authors.forename: M
authors.initials: M
authors.lastname: Campiglio
authors.forename: M
authors.initials: M
authors.lastname: Sandri
authors.forename: M
authors.initials: M
authors.lastname: Sasso
authors.forename: F
authors.initials: F
authors.lastname: Bianchi
authors.forename: A
authors.initials: A
authors.lastname: Balsari
authors.forename: S
authors.initials: S
authors.lastname: Ménard
authors.forename: E
authors.initials: E
authors.lastname: Tagliabue
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab; D047368:Tumor Burden
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human